For the long-term treatment of patients with chronic heart failure, there is as yet no satisfactory substitute for cardiac glycosides. But the availability of drugs with selective inotropic and reduced electrophysiologic effects may not be far off. Even then, inotropic therapy will probably have to be handled with great care and awareness of the inherent risks.